jupiterneurosciences.com (JUNS) - התחייבויות לטווח ארוך להון

Jupiter Neurosciences Inc (JUNS) is spending its accumulated funds on the development of Alzheimer's therapy, which is creating financial pressure. This daily price chart from the GURU.Markets platform shows the ratio of long-term liabilities to equity, where the metric value is 0.00. Price growth is supported by physician-involved automated drug synthesis and the unique bioavailability of the JOTROL platform, providing the company with full pricing power upon market entry.

Jupiter Neurosciences Inc (JUNS) focuses on the development of the innovative drug JPC-033 for the therapy of neurodegenerative pathologies. An analysis of the long-term debt-to-equity structure allows for an assessment of the funding stability for the R&D stage. This indicator determines the share of credit obligations with a maturity of more than one year relative to the total value of net assets. Increasing leverage may boost equity returns, but it raises the risk of interest expenses. A low value for this metric confirms the company's financial autonomy.